A recent meta-analysis demonstrated an association between aspirin and a reduced risk of prostate cancer.
The anticancer drug galeterone has proved successful in lowering prostate-specific antigen levels in men with castration-resistant prostate cancer (CRPC).
Men receiving hormone therapy for prostate cancer may be missing out on protective meds, researchers say.
A new anticancer drug, already in clinical development, may help spare healthy cells from the effects of radiation treatments.
A genetic test has been developed to identify which men are at higher risk for prostate cancer recurrence after localized treatment with surgery or radiotherapy.
Phosphorous is independently associated with the risk of developing lethal and high-grade prostate cancer.
Prostate cancer patients with hereditary mutations in the BRCA genes do not respond as well to conventional treatment such as surgery and radiotherapy, and they have a lower survival rate than patients who do not have these genetic mutations.
Olaparib, an experimental oral cancer drug, has shown an overall tumor response rate of 26% in advanced cancers associated with BRCA1 and BRCA2 mutations, according to recent research.
A new technique that employs advanced MRI scans to diagnose prostate cancer is being tested in a nationwide trial.
Metformin use associated with decreased risk of prostate cancer diagnosis while other oral antihyperglycemics had no decreased risk.
Less than 20 percent of top-ranked health sites advise against screening for prostate cancer, a recommendation made by the USPSTF.
Active surveillance allows men with prostate cancer to delay or avoid the side effects of its treatment as well.
A video-based educational tool increased comprehension of prostate health terms in patients with a mean literacy level of 7th grade or higher.
Molecular tests are poised to become a part of the treatment guidelines for prostate cancer. These tests provide information that extends beyond just identifying the type of cancer a patient has; they can also help narrow down treatment options to those that offer the best outcomes for patients.
Some prostate cancer medications are linked to an increased risk of dying from heart-related causes in men with congestive heart failure or with a history of prior heart attacks.
The endorsed guideline outlines use of adjuvant and salvage radiotherapy after surgery for prostate cancer.
Androgen deprivation therapy may increase risk of cardiac-related death in patients with cardiac issues
Men who were treated with androgen deprivation therapy for prostate cancer have a three times increased risk of cardiac problems.
Even a small daily dose of aspirin may help lower mortality among men with nonmetastatic prostate cancer, according to research.
Consuming 10 portions of tomatoes a week can reduce risk for developing prostate cancer by 18%.
Primary androgen deprivation therapy (PADT) was linked with increased all-cause mortality and prostate cancer-specific mortality.
For patients with low-risk prostate cancer managed with active surveillance, obesity may increase risk of progression
Obesity is linked with increased risk of progression of low-risk prostate cancers in active surveillance.
For some men, prostate cancer recurrence may be overdetected, especially in those aged over 70.
Researchers sought to determine which types of patients die from prostate cancer in the modern era.
Some patients whose PSA levels become elevated after prostatectomy may die as a result of a cause unrelated to prostate cancer.
Findings suggest that elevated levels of cholesterol and triglycerides may be linked with greater risk of the prostate cancer recurrence, but normalization of blood fats may reduce risk.
The effect of guidelines recommending that elderly men should not be routinely screened for prostate cancer has been minimal at best, according to a new study.
High cholesterol may be associated with an increased risk for developing prostate cancer.
Testosterone increased the risk for developing prostate cancer in rats.
Aspirin and other other NSAIDs were associated with a decreased risk for developing an aggressive form of prostate cancer.
Frank dela Rama, a new member of the Oncology Nurse Advisor editorial board, talks about helping men with newly diagnosed prostate cancer learn about and prepare to cope with their disease.
Prostate cancer treatment controversy continues as study finds watchful waiting not enough for some men
An active controversy among oncologists concerns watchful waiting versus more active treatment for prostate cancer.
Researchers have discovered that men who are not well educated about their prostate cancer have a much more difficult time deciding on treatment options.
Chokeberry extract enhances cytotoxicity of gemcitabine on a single cancer cell line, according to research.
Guidelines recommending clinicians not routinely screen elderly men for prostate cancer have had a minimal effect on practice.
High rates of preserved sexual function seen with combination beam plus brachytherapy for prostate cancer.
Shorter time to testosterone recovery with 18 versus 36 months androgen deprivation therapy.
Baldness in men at age 45 is linked with an elevated risk for developing aggressive prostate cancer.
For men with early-stage prostate cancer, watching waiting is not always the best course of action, especially for black patients.
Enzalutamide reduces skeletal-related events in men with advanced castration-resistant prostate cancer
Enzalutamide was found to decrease the risk of skeletal-related events in men with metastatic castration-resistant prostate cancer.
Recommendations are for men whose tumors have grown resistant to hormonal therapies were issued jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) in Canada.
There has been widespread adoption in the United States of robot-assisted prostatectomy to treat prostate cancer in recent years.
African American men may not benefit from watchful waiting after being diagnosed with low-grade prostate cancer.
Researchers have designed a new, non-invasive technique to screen for prostate cancer.
For economically disadvantaged men with newly diagnosed prostate cancer, poor knowledge about prostate cancer is associated with increased decisional conflict.
Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all trial steps are most likely to undergo a biopsy at the end of the trial, according to recent research.
Researchers found that men who aren't well educated about prostate cancer have more difficulty making decisions.
Men who eat more than 10 portions of tomatoes each week have an 18% lower risk of developing prostate cancer.
A calculator to help men and their doctors assess the risk of prostate cancer has had a major upgrade to enhance men's and their physicians' understanding of a man's risk of prostate cancer.
Men without prostate cancer taking part in the trial who participate in other aspects are most likely to undergo a challenging biopsy.
Prostate-specific antigen (PSA) screening is associated with a lasting reduction in prostate cancer mortality, according to a study published online.
A genomic tool can help doctors and patients make a more informed decision on the need for radiation therapy after surgery for prostate cancer.
Men with diagnosed depressive disorders are less likely to pursue definitive treatment options for prostate cancer and more likely to have poorer outcomes.
Robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years, according to a new study.
Although their lives eventually return to normal after treatment, some men have to cope with lingering effects of their treatment that affects their libido or sexual function. Daniel Watter, EdD, offers guidance tips to share with patients who are surviving prostate cancer that can help them through the recovery process.
Two independent trials have validated the performance of an epigenetic test that could provide physicians with a better tool to help eliminate unnecessary repeat prostate biopsies.
A study of people who were adopted identified genetics as the dominant risk factor in familial breast, prostate, and colorectal cancers.
Vasectomy was associated with a small increased risk of prostate cancer, and a stronger risk for advanced or lethal prostate cancer, according to a new study.
A research team from Japan found that 16-core biopsy has a slightly higher detection rate than 12-core biopsy.
Researchers found that cyclists who bike more may face a higher risk of prostate cancer, but not a greater chance of infertility or erectile dysfunction.
Rates of observation as management for low-risk prostate cancer vary widely, and primary ADT is not tied to better survival for men with localized prostate cancer.
Results of a new study show that robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years.
Vasectomy is associated with an increased incidence of prostate cancer overall during extended follow-up, with an elevated risk seen for high-grade and lethal cancer.
Depressed men with a diagnosis of intermediate- or high-risk prostate cancer have worse overall outcomes.
Physicians who diagnosed low-risk prostate cancer had more influence over the decision to enter active surveillance than did the disease characteristics, according to a case review.
Key genetic variants may affect how cancer patients respond to radiation treatments, according to a new study.
Researchers searching for a target that would interfere with cancer metastasis identified a new suppressor of metastasis that may lead toward the development of more effective treatments for prostate cancer and other malignant solid tumors.
Hot flashes are a common side effect of menopausal changes experienced by women; however, they can also be a hormone-related effect experienced by men with prostate cancer.
A new study is suggesting a different approach to treating prostate cancer. Researchers at Comprehensive Cancer Centers of Nevada conducted a study in which 790 men with advanced stages of prostate cancer received early chemotherapy.
The loss of the p62 protein in tumor cells and the surrounding tissue can enhance the growth and progression of tumors, according to research from Sanford Burnham Medical Research Institute. The findings add to the acknowledgement that the stroma is an integral part of cancer initiation, growth, and expansion.
Specialists who treat prostate cancer agree that active surveillance is an effective option for patients with low-risk prostate cancer; however, most are more likely to recommend the treatment provided by their own specialties.
In an international randomized phase III clinical trial, the hormone therapy enzalutamide extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy.
Although most prostate cancer specialists believe active surveillance to be effective and underused, fewer endorse active surveillance than other therapies for low-risk prostate cancer.
A groundbreaking molecular imaging agent has been developed to help clinicians find as much prostate cancer as possible and determine whether it is responding favorably or not.
Specialists who treat prostate cancer agree that active surveillance is an effective option—yet according to a study most don't recommend it when appropriate for their own patients.
A study from the University of Iowa examined the charge for prostate cancer surgery at 100 hospital all over the United States, and the results showed widely different prices.
Gonadotropin-releasing hormone-I (GnRH-I) has attracted strong attention as a hormonal therapeutic tool, particularly for androgen-dependent prostate cancer patients. Here, we investigated the effect of SN09-2 on the growth of PC3 prostate cancer cells.
Male patients with prostate cancer, and patients with other genitourinary cancers, need information on how their cancer and its treatment will affect their life.
Improved diagnosis and management of prostate cancer could result from research that has discovered that seminal fluid contains biomarkers for the disease.
New guidelines have been developed for clinical follow-up care for prostate cancer survivors. Issues addressed include health promotion, surveillance for recurrence, and new primaries.
The American Cancer Society released a set of guidelines addressing the long-term primary care for survivors of prostate cancer. The guidelines outline follow-up care, monitoring for recurrence, and screening for secondary primary cancers. They also reiterate the need to educate survivors about physical exercise and smoking cessation.
An enzyme commonly used as a target for antidepressants may also promote prostate cancer growth, according to an international team of scientists.
A new screening technique, MR fusion guided prostate biopsy, holds promise for increased prostate cancer detection.
The Prolaris test distinguished newly diagnosed patients who were likely to die from prostate cancer within 10 years from those with lower risk disease.
Improved diagnosis and management of prostate cancer could result from research at the research at the University of Adelaide, which has discovered that seminal fluid (semen) contains biomarkers for the disease.
Researchers have developed a new technique to combat metastatic prostate cancer (which is called castration-resistant), which could delay the start of chemotherapy.
Many people are unaware that prostate cancer may sometimes be transmitted sexually.
Circumcision appears to confer a protective effect against the development of prostate cancer, according to research published online.
There's new evidence that certain drugs used to treat depression might also help stop the growth of prostate cancer.
Enzalutamide, an oral androgen-receptor inhibitor, is superior to placebo for the treatment of metastatic prostate cancer before chemotherapy, according a study.
Claims of not receiving proper informed consent and clinical performance are the main issues that arise in radical prostatectomy malpractice lawsuits.
Upfront standard androgen deprivation therapy plus six cycles of docetaxel significantly improves overall survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.
For the approximately 60,000 men in the United States with prostate cancer who are asymptomatic after radical primary treatment yet have a PSA relapse, it's safe to postpone androgen deprivation therapy, a study presented at the 2014 American Society of Clinical Oncology Annual Meeting concluded.
The site of metastatic tumors powerfully predicts overall survival (OS) among men with metastatic castration resistant prostate cancer (mCRPC), confirms a meta-analysis presented at the 2014 American Society of Clinical Oncology Annual Meeting.
Treating older men with early stage prostate cancer who also have other serious health problems with aggressive therapies does not help them live longer and, in fact, can be detrimental.
A commercial test designed to rule out the presence of genetic biomarkers of prostate cancer could exclude the need for repeat prostate biopsies in many patients.
Targeted prostate biopsy using multi-parametric magnetic resonance imaging-ultrasound fusion may lead to reclassification of prostate cancer that was initially diagnosed as low-risk, according to research.
Vitamin D deficiency was an indicator of aggressive prostate cancer and spread of the disease in men who underwent their first prostate biopsy because of abnormal PSA test and/or DRE results.
For men with early-stage prostate cancer, the cancer-specific survival benefit associated with aggressive prostate cancer treatment is reduced with increasing comorbidity, according to a study.
A novel noninvasive technique can detect prostate cancer using an electronic nose.
- Key discovery in understanding successes and failures of immunotherapy
- Researchers identify biological indicator of response to new ovarian cancer drug
- Added sugars may increase blood pressure more than high salt consumption
- Managing obesity should be part of cancer care
- Galeterone active in one form of castration-resistant prostate cancer
- Navigation and survivorship: Rationalizing your program costs
- Monitoring psychosocial function in radiotherapy
- Comparison of medications for managing nausea and vomiting
- Comparison of constipation management medications
- Chemo- and immunotherapy combination is a promising treatment for pancreatic cancer
- High tumor immune cell levels may identify women with HER2+ breast cancer who may benefit from chemotherapy alone
- Hair Dyes and Cancer Risk (Fact Sheet)
- For bladder cancer, laparoscopic radical cystectomy effective at preventing recurrence
- Aspirin and/or NSAID use may improve risk of high-grade prostate cancer
- Modifying lifestyle, HPV vaccine can help prevent anal cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|